Format

Send to

Choose Destination
See comment in PubMed Commons below
Urol Oncol. 2011 Jan-Feb;29(1):85-9. doi: 10.1016/j.urolonc.2008.10.017. Epub 2008 Dec 25.

Immunohistochemical basis for adjuvant anti-angiogenic targeted therapy for renal carcinoid: initial case report.

Author information

1
Department of Urology, University of California Irvine Medical Center, Orange, CA 92868, USA. finds@uci.edu

Abstract

OBJECTIVES:

To evaluate the immunohistochemical profile of a carcinoid (low grade neuroendocrine tumor of the kidney) from a patient with lymph node positive disease who remains disease free for 31 months after radical nephrectomy, lymph node dissection, and adjuvant therapy with sunitinib malate.

METHODS:

Immunohistochemical staining was performed for chromogranin, synaptophysin, CD31, VEGF, HIF-1α, HIF-2, and Glut-1. Staining was evaluated in 3 high-power fields and samples scored as strongly positive (3+), moderately positive (2+), weakly positive (1+), or negative (0). A clear cell renal cell carcinoma was used as positive control.

RESULTS:

Immunohistochemical staining was strongly positive VEGF, weak to moderately positive for HIF-2, and negative for HIF-1α and Glut-1.

CONCLUSIONS:

Our case of primary renal carcinoid stained intensely for VEGF and HIF-2, consistent with a VHL-HIF1-HIF2-Glut1 independent pathway for VEGF activation. These data suggest that like other neuroendocrine tumors, primary renal carcinoid is a potential target for anti-angiogenic therapy with sunitinib.

PMID:
19110452
PMCID:
PMC4519232
DOI:
10.1016/j.urolonc.2008.10.017
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center